Clinical manifestations and treatment of mucopolysaccharidosis type i patients in Latin America as compared with the rest of the world

Background Mucopolysaccharidosis I (MPS I) comprises a spectrum of clinical manifestations and is divided into three phenotypes reflecting clinical severity: Hurler, Hurler- Scheie, and Scheie syndromes. There may be important variations in clinical manifestations of this genetic disease in patients...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2011
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/22381
Acceso en línea:
https://doi.org/10.1007/s10545-011-9336-2
https://repository.urosario.edu.co/handle/10336/22381
Palabra clave:
Age
Article
Clinical feature
Cognitive defect
Controlled study
Cornea disease
Disease registry
Disease severity
Enzyme replacement
Geographic distribution
Hematopoietic stem cell transplantation
Hepatomegaly
Human
Hurler scheie syndrome
Hurler syndrome
Joint contracture
Kyphosis
Major clinical study
Mucopolysaccharidosis
Onset age
Phenotypic variation
Pneumonia
Prevalence
Scheie syndrome
Scoliosis
Sleep disorder
Snoring
South and central america
Tongue swelling
Tonsil disease
Valvular heart disease
Adolescent
Adult
Age of onset
Child
Comorbidity
Enzyme replacement therapy
Female
Geography
Hematopoietic stem cell transplantation
Humans
Iduronidase
Infant
Latin america
Male
Middle aged
Mucopolysaccharidosis i
Phenotype
Registries
Time factors
World health
Young adult
differential
newborn
preschool
Child
Diagnosis
Infant
Rights
License
Abierto (Texto Completo)
Description
Summary:Background Mucopolysaccharidosis I (MPS I) comprises a spectrum of clinical manifestations and is divided into three phenotypes reflecting clinical severity: Hurler, Hurler- Scheie, and Scheie syndromes. There may be important variations in clinical manifestations of this genetic disease in patients residing in different regions of the world. Methods Using data from the MPS I Registry (as of September 2009), we evaluated patients from Latin America (n=118) compared with patients from the rest of the world [ROW (n=727)]. Results Phenotype distribution differed among patients in Latin America compared to ROW(Hurler 31 vs. 62%, Hurler- Scheie 36 vs. 21%, Scheie 10 vs. 11%, and unknown 22 vs. 6%). The frequency of certain symptoms, such as cardiac valve abnormalities, sleep impairment, and joint contractures, also differed between Latin America and ROW for some phenotypes. Median age at MPS I diagnosis was earlier in the ROW than Latin America for all phenotypes, and age at first treatment for Hurler and Hurler-Scheie patients was also earlier in the ROW. Hurler patients in Latin America showed a gap of 3.1 years between median ages of diagnosis and first treatment compared to only 0.5 years in the ROW. Treatment allocation in Latin America compared to ROW was as follows: enzyme replacement therapy (ERT) only, 80 vs. 45%; hematopoietic stem cell transplantation (HSCT) only, 0.9 vs. 27%; both ERT and HSCT, 0 vs. 16%; and neither treatment, 19 vs. 13%. Conclusion These data highlight important differences in MPS I patients between Latin America and ROW in terms of phenotypic distribution, clinical manifestations, and treatment practices. © The Author(s) 2011.